Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules

Journal of Nuclear Medicine

Volumn 51, Issue 6, 2010, Pages 892-897

  Baum, Richard P ^a   Prasad, Vikas ^a   Müller, Dirk ^a   Schuchardt, Christiane ^a   Orlova, Anna ^b,c   Wennborg, Anders ^b   Tolmachev, Vladimir ^b,c   Feldwisch, Joachim ^b,c  

^a ZENTRALKLINIK BAD BERKA   (Germany)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

111In; 68Ga; Breast cancer; Diagnostic imaging; PET CT

Indexed keywords

ABY 002 GA 68; ABY 002 IN 111; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; NAVELBINE; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; GALLIUM; HYBRID PROTEIN; INDIUM;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BREAST TUMOR; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; INJECTION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE;

ADULT; BREAST NEOPLASMS; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS; MIDDLE AGED; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953927395     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.073239     Document Type: Article

References (20)

1. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer. 2008;8:94-107.
2. Baum RP, Prasad V. Molecular imaging for monitoring therapy response. In: Cook GJR, Maisey M-N, Britton KE, Chengazi V, eds. Clinical Nuclear Medicine. 4th ed. London: U. K.: Oxford University Press; 2007: 57-79.
3. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu protooncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953-962.
4. Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics. 2009;3:289-301.
5. Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281-293.
6. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
7. Tuma RS. Inconsistency of HER2 test raises questions. J Natl Cancer Inst. 2007;99:1064-1065.
8. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93:552-556.
9. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res. 2007;9:R31.
10. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14:2999-3019.
11. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic Affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178-2186.
12. 18F-labeled Affibody molecules. J Nucl Med. 2009;50:1131-1139.
13. HER2:342-Affibody molecule: a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2008;35:1008-1018.
14. European Medicines Evaluation Agency. Trastuzumab scientific discussion. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Herceptin/177400en6. pdf. Accessed March 18, 2010.
15. Human Protein Atlas. Version 5.0. Available at: http://www.proteinatlas. org. Accessed March 18, 2010.
16. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med. 2001;345:995-996.
17. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282.
18. 111Indium- trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046-2051.
19. Akhurst T, Morris PG, Modi S, et al. Positron emission tomography (PET) with radiolabeled F (ab') 2-trastuzumab fragments in patients (pts) with HER2-positive metastatic breast cancer (MBC): initial feasibility results. Poster presented at 2008 Breast Cancer Symposium; September 5-7, 2008; Washington, DC. Abstract 79.
20. 89Zrtrastuzumab in metastatic breast cancer patients [abstract]. J Clin Oncol. 2009;27(suppl):1045.